How to Get Praluent (Alirocumab) in Oregon

What Is Praluent and Why Oregon Patients Are Prescribed It

Praluent is a monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. By inhibiting PCSK9, alirocumab allows more LDL receptors to remain active, which drives LDL-C out of the bloodstream. The FDA granted initial approval in July 2015, and the full prescribing information is available through the FDA label database.

Oregon prescribers use alirocumab for two principal patient populations. The first group has heterozygous familial hypercholesterolemia (HeFH), a genetic condition affecting roughly 1 in 250 people in which LDL-C remains dangerously elevated despite diet and statin therapy. The second group has established atherosclerotic cardiovascular disease (ASCVD) and cannot achieve guideline-recommended LDL-C targets on maximally tolerated statins alone.

The landmark ODYSSEY OUTCOMES trial (N=18,924) compared alirocumab 75 to 150 mg every two weeks against placebo in patients who had experienced an acute coronary syndrome within the prior year while on high-intensity statins. Published in the New England Journal of Medicine in 2018, the trial demonstrated a 15% relative risk reduction in the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001). In the pre-specified subgroup with baseline LDL-C at or above 100 mg/dL, the absolute risk reduction was 3.4 percentage points over a median of 2.8 years, translating to a number needed to treat of 29.

Alirocumab is not a compounded peptide or a supplement. Oregon 503A compounding pharmacies cannot legally manufacture biological monoclonal antibodies, so patients must obtain the branded Praluent product through an FDA-regulated specialty pharmacy.

How Oregon Prescribing Laws Apply to Praluent

Oregon law permits licensed physicians (MDs and DOs), nurse practitioners (NPs), and physician assistants (PAs) to prescribe alirocumab, provided the prescriber holds an active Oregon DEA number (not strictly required for this non-controlled drug, but a valid Oregon prescriber license is mandatory) and a valid DEA-independent state prescribing license with controlled-substance authority not being required for this medication specifically.

Telehealth prescribing for non-controlled medications in Oregon is explicitly permitted under Oregon Revised Statutes and the Oregon Medical Board's telehealth rules, which align with the post-pandemic regulatory framework solidified in 2023. A prescriber conducting a telemedicine visit must establish a valid patient-provider relationship, which in Oregon does not require a prior in-person encounter for non-controlled substances. This means a new patient in Portland, Eugene, Bend, or any rural Oregon county can complete a video consultation with a licensed Oregon telehealth provider and receive a Praluent prescription the same day if clinical criteria are met.

The Oregon Board of Nursing grants NPs full independent prescribing authority. A nurse practitioner specializing in cardiology or lipid management can therefore prescribe alirocumab without physician co-signature, making telehealth NP-led lipid clinics a practical access route for Oregonians outside major metro areas.

PAs in Oregon must have a practice agreement with a supervising physician, but that agreement does not require the supervising physician to be present during every patient encounter. A PA working for a telehealth platform can prescribe Praluent as long as the practice agreement covers cardiovascular or lipid management.

Step-by-Step Process to Get Praluent in Oregon

Getting Praluent involves four sequential steps: clinical evaluation, prescription generation, prior authorization, and specialty pharmacy dispensing. Each step has a predictable timeline that Oregon patients should plan around.

Step 1. Clinical evaluation (Day 1 to Day 3)

Schedule a visit with a cardiologist, lipidologist, or telehealth provider licensed in Oregon. Bring or arrange transfer of any prior lipid panels, statin trial records, and documentation of statin intolerance if applicable. The provider will review your LDL-C history, calculate your 10-year ASCVD risk using the Pooled Cohort Equations, and confirm that you meet the ACC/AHA threshold for PCSK9 inhibitor therapy. The 2022 ACC Expert Consensus Decision Pathway on nonstatin therapies states that PCSK9 inhibitor therapy is reasonable when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients on maximally tolerated statin therapy, or at or above 100 mg/dL in high-risk patients.

Step 2. Prescription generation (Day 1 to Day 5)

After the clinical evaluation, the prescriber sends the prescription electronically to a specialty pharmacy. Praluent requires cold-chain shipping (stored between 36 and 46 degrees Fahrenheit) and is not stocked at retail pharmacies in Oregon. Specialty pharmacies that dispense alirocumab in Oregon include Accredo, CVS Specialty, Walgreens Specialty, and several regional options operating within the state.

Step 3. Prior authorization (Day 2 to Day 21)

This is the rate-limiting step. Every major Oregon payer, including PacificSource, Moda Health, Providence Health Plan, and Oregon Health Plan (Medicaid), requires PA before dispensing Praluent. The prescriber's office submits the PA request with supporting documentation. Typical required documents include a current fasting lipid panel (drawn within 90 days), documentation of two failed statin trials at maximally tolerated doses (or one failed trial plus a documented statin intolerance), the patient's ASCVD event history or confirmed FH diagnosis, and the specific LDL-C value that prompted the request.

Oregon Medicaid (OHP) covers alirocumab under its Prioritized List of Health Services when the patient carries an ICD-10 code for familial hypercholesterolemia (E78.01 for HeFH) or established ASCVD with documented inadequate statin response. The PA review period under OHP is 14 business days for standard requests and 72 hours for urgent requests.

Step 4. Specialty pharmacy dispensing (Day 7 to Day 21 post-PA approval)

Once PA is approved, the specialty pharmacy ships Praluent in a temperature-controlled package directly to the patient's Oregon address. The autoinjector format (either the single-dose prefilled pen or the single-dose prefilled syringe) arrives with a sharps disposal kit. First-time patients receive injection training materials; telehealth patients can also complete video-based injection training with a pharmacy nurse.

Labs and Workup Required Before Starting Praluent in Oregon

Oregon providers generally require a baseline laboratory workup before writing the first Praluent prescription. Fasting lipid panel is essential. Most insurers will not approve PA without an LDL-C value drawn within the prior 90 days. A comprehensive metabolic panel (CMP) checks renal and hepatic function, since liver disease may alter drug metabolism and is relevant for statin co-administration. Thyroid-stimulating hormone (TSH) is ordered when secondary causes of hypercholesterolemia are suspected, particularly in patients with new-onset or worsening dyslipidemia.

Alirocumab itself does not require liver function monitoring during therapy. The FDA label does not mandate routine LFT surveillance after initiation, unlike older lipid-lowering agents. A follow-up fasting lipid panel at 4 to 8 weeks after the first injection is standard practice to confirm LDL-C response and guide dose titration. ODYSSEY LONG TERM (N=2,341) showed that patients starting at 150 mg every two weeks achieved mean LDL-C reductions of 61% at week 24 compared with placebo. That data is referenced in the PubMed record PMID 25773378.

If a patient is simultaneously being managed for diabetes, the prescriber may also check HbA1c, since high-intensity statins carry a modest risk of new-onset diabetes and the lipid panel often prompts a broader metabolic review.

Prior Authorization Documentation for Oregon Payers

Prior authorization is the single largest barrier Oregon patients face. Knowing exactly what to submit shortens the process from three weeks to closer to five business days in many cases.

The core documentation bundle for Oregon PA requests typically includes:

A dated fasting lipid panel showing the current LDL-C value. For ASCVD patients, payers want to see LDL-C at or above 70 mg/dL on maximally tolerated statin therapy. For HeFH patients, LDL-C at or above 100 mg/dL is the typical threshold, though some payers lower this to 70 mg/dL when additional risk factors are present.

Documentation of maximally tolerated statin therapy. This means the prescriber must show either that the patient failed two statins at the highest dose that produced a trial of at least 4 to 8 weeks, or that the patient has documented statin intolerance supported by CPK levels, symptom records, and a re-challenge attempt.

The patient's cardiovascular history. Hospital discharge summaries from MI, PCI, CABG, or stroke events carry the most weight. For FH patients, a Dutch Lipid Clinic Network score of 6 or higher is accepted by most Oregon payers as diagnostic evidence of HeFH.

A letter of medical necessity from the prescriber. This document should cite the patient's specific LDL-C values, list the statins trialed, reference the ACC/AHA guideline threshold, and state the clinical rationale for Praluent over ezetimibe alone, if ezetimibe has already been trialed.

Oregon prescribers who prepare a single complete PA bundle upfront, rather than submitting piecemeal in response to payer requests for additional information, reduce the average PA processing time from 14 days to approximately 6 to 8 days based on patterns seen in Oregon specialty pharmacy workflows. The HealthRX Oregon Lipid PA Checklist (reviewed by the HealthRX medical team) consolidates these requirements into a single pre-submission workflow that providers can complete in under 20 minutes.

Praluent Telehealth Access in Oregon: How It Works

Oregon telehealth laws explicitly allow prescribers to write new prescriptions for non-controlled drugs after a synchronous audio-video visit. Alirocumab is not a controlled substance, which removes the key federal and state restrictions that apply to medications like testosterone or benzodiazepines.

A typical Oregon telehealth Praluent visit runs 20 to 30 minutes. The provider reviews uploaded lab results, confirms the clinical history via structured intake, and renders a prescribing decision at the end of the visit. The prescription is transmitted electronically to the patient's preferred specialty pharmacy, and the PA process launches the same day.

Telehealth access is especially relevant for Oregonians in Eastern Oregon, the Oregon Coast, and Southern Oregon, where specialist wait times for in-person cardiology appointments can reach 8 to 16 weeks. A telehealth lipid consultation closes that gap entirely for patients who have existing lab work. Patients in Medford, Klamath Falls, La Grande, and Coos Bay have used Oregon-licensed telehealth platforms to initiate Praluent therapy and receive their first shipment before a local specialist appointment would have been available.

The American College of Cardiology's 2023 telehealth guidance notes that lipid management is among the cardiovascular subspecialties most amenable to virtual care, given that clinical decisions rest primarily on laboratory data rather than physical examination findings.

Dosing, Administration, and What to Expect After Your First Injection

Alirocumab is available in two doses. The 75 mg/mL prefilled pen delivers 75 mg per injection; the 150 mg/mL prefilled pen delivers 150 mg per injection. The standard starting dose is 75 mg subcutaneously every two weeks. If LDL-C response is inadequate at 4 to 8 weeks, the dose may be titrated to 150 mg every two weeks. Patients who prefer a monthly injection schedule can use the 300 mg dose (two simultaneous 150 mg injections) every four weeks, which the FDA approved in 2018.

Injection sites include the abdomen, upper arm, and thigh. The autoinjector design does not require needle exposure before or after injection. Patients should rotate injection sites and avoid areas of active skin irritation or bruising.

LDL-C begins falling within 14 days of the first injection. By week 8, the full steady-state reduction is typically established. In ODYSSEY OUTCOMES, patients on alirocumab reached a median on-treatment LDL-C of 53 mg/dL, compared with 101 mg/dL in the placebo group, a difference that persisted across all pre-specified subgroups including patients with diabetes, prior stroke, and multivessel coronary disease.

The most common adverse effects reported in trials were injection-site reactions (occurring in 7.2% of alirocumab-treated patients versus 5.1% in placebo), nasopharyngitis, and influenza-like illness. Serious hypersensitivity reactions, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization, have been reported rarely; patients should be instructed to discontinue Praluent and seek care immediately if they develop severe rash, facial swelling, or difficulty breathing.

Storage in Oregon requires the patient to maintain the drug in a home refrigerator at 36 to 46 degrees Fahrenheit. Praluent may be stored at room temperature (below 77 degrees Fahrenheit) for up to 30 days once removed from the refrigerator, which is relevant for Oregon travelers and outdoor workers.

Cost, Copay Assistance, and Oregon Medicaid Coverage

The list price for Praluent in the United States is approximately $5,850 per year, though most commercially insured patients pay far less after insurance adjudication. Regeneron and Sanofi operate a copay card program (Praluent360) that reduces out-of-pocket costs to as low as $0 per month for eligible commercially insured Oregon patients. The copay program does not apply to Medicare or Medicaid beneficiaries under federal law.

Oregon Health Plan (OHP) covers alirocumab for members whose diagnosis codes and clinical documentation satisfy the PA criteria described earlier. OHP members pay no cost-sharing for covered specialty drugs. The OHP Prioritized List condition for Praluent coverage (FH or ASCVD with documented inadequate statin response) aligns closely with the ACC/AHA guideline indications.

Medicare Part D coverage for Praluent varies by plan. Oregon Medicare beneficiaries should check the specific formulary of their Part D plan each year, as tier placement and step-therapy requirements differ across plans. The Medicare Extra Help program may cover a portion of costs for low-income beneficiaries.

Uninsured Oregon residents face the full list price but may qualify for Regeneron's patient assistance program, which provides Praluent at no charge to patients meeting income eligibility thresholds (generally at or below 400% of the federal poverty level). Applications are submitted through the manufacturer directly and typically processed within 10 to 14 business days.

Transferring a Praluent Prescription to Oregon

Patients relocating to Oregon from another state with an existing Praluent prescription face a straightforward but time-sensitive process. Oregon law does not allow pharmacies to honor out-of-state PA approvals directly. The new Oregon prescriber must re-submit a PA request to the Oregon payer using Oregon-specific documentation requirements.

To minimize a gap in therapy, patients should schedule a telehealth or in-person Oregon provider visit before or within the first week of relocation. The transferring provider should supply a clinical summary including recent lipid panels, the PA approval history from the prior state, and a list of prior statin trials. This documentation does not guarantee automatic PA approval in Oregon, but it substantially shortens the review process because the new prescriber can submit a complete bundle on day one rather than assembling records over two to three weeks.

The specialty pharmacy used in the prior state can often arrange a bridge supply of 30 days while the Oregon PA is processed. Patients should explicitly ask their specialty pharmacy about bridge supply policies before the move.

Alirocumab vs. Evolocumab in Oregon: Choosing Between the Two PCSK9 Inhibitors

Oregon prescribers sometimes face a formulary decision between alirocumab (Praluent) and evolocumab (Repatha), the other FDA-approved PCSK9 inhibitor. Both drugs produce comparable LDL-C reductions in head-to-head pharmacokinetic studies, and both are covered by Oregon Medicaid with PA. Formulary tier placement on commercial plans varies by payer and changes annually.

The clinical distinction is subtle. ODYSSEY OUTCOMES demonstrated cardiovascular outcome benefit for alirocumab specifically in post-ACS patients with LDL-C at or above 100 mg/dL. FOURIER (N=27,564), published in the same year, demonstrated evolocumab's cardiovascular outcome benefit across a broader stable ASCVD population. A prescriber choosing between the two agents for a specific Oregon patient should check the patient's current insurance formulary first; the drug on a lower tier will cost the patient less and may face fewer step-therapy requirements.

As reported in the Journal of the American College of Cardiology, both agents are effective at achieving guideline-recommended LDL-C targets below 70 mg/dL in high-risk patients when added to maximally tolerated statin therapy.

What Oregon Providers Say About Alirocumab Prescribing

The ACC/AHA 2018 Multisociety Guideline on the Management of Blood Cholesterol states directly: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C levels remain greater than or equal to 70 mg/dL despite maximally tolerated statin and ezetimibe therapy." The guideline is indexed at PubMed PMID 30586774. Oregon providers operating within standard-of-care norms are expected to document adherence to this threshold when requesting PA.

The National Lipid Association has taken a similar position, supporting PCSK9 inhibitor use in patients whose non-HDL-C remains above 100 mg/dL on maximally tolerated therapy, particularly when lipoprotein(a) elevation compounds total cardiovascular risk. Oregon patients with both high LDL-C and elevated Lp(a) represent a population where alirocumab may provide the most benefit, since ODYSSEY OUTCOMES showed a 23% reduction in major cardiovascular events in the highest Lp(a) quartile.